Wikisage, the free encyclopedia of the second generation, is digital heritage
Amifampridine: Difference between revisions
Jump to navigation
Jump to search
(→ATC) |
m (→Links) |
||
| Line 15: | Line 15: | ||
[https://www.fda.gov/drugs/resources-information-approved-drugs/drug-trial-snapshot-firdapse?utm_campaign=FIRDAPSE%3A%20New%20Drug%20Trials%20Snapshot%20Posted&utm_medium=email&utm_source=Eloqua&elqTrackId=c2f2cdb9b5df4474865ad177537e17cd&elq=b0824506823d49a8915422ef2620ec8a&elqaid=6329&elqat=1&elqCampaignId=5158 Drug Trial Snapshot: Firdapse] | [https://www.fda.gov/drugs/resources-information-approved-drugs/drug-trial-snapshot-firdapse?utm_campaign=FIRDAPSE%3A%20New%20Drug%20Trials%20Snapshot%20Posted&utm_medium=email&utm_source=Eloqua&elqTrackId=c2f2cdb9b5df4474865ad177537e17cd&elq=b0824506823d49a8915422ef2620ec8a&elqaid=6329&elqat=1&elqCampaignId=5158 Drug Trial Snapshot: Firdapse] | ||
{{refs}} | |||
{{Wikidata|Q411707}} | {{Wikidata|Q411707}} | ||
Latest revision as of 01:15, 7 May 2019
Amifampridine phosphate was granted an Orphan Drug designation by the FDA for MG in September 2016, shortly after receiving a Refusal to File letter from the FDA for its submission for the treatment of congenital myasthenic syndromes and Lambert Eaton myasthenic syndrome (LEMS [1])[2]
ATC
Links
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder Drug Trial Snapshot: Firdapse
| References: |
